Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07205926 · ClinicalTrials.gov registry record · Phase 1
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
A Phase 1 study of Diarrhea and Shigella, sponsored by Inventprise.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07205926: Recruiting Phase 1 study of Diarrhea and Shigella, sponsored by Inventprise.
NCT07205926 is a Phase 1 study of Diarrhea and Shigella that is actively recruiting participants, run by Inventprise. The registered enrollment target is 60 participants, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07205926, a Phase 1 study of Diarrhea and Shigella, is actively recruiting participants, sponsored by Inventprise.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
Primary Outcome
To assess the safety and tolerability of a 2-dose IM regimen of 5 formulations of IVT Shigella-04
Interventions
- BIOLOGICAL IVT Shigella-04
- BIOLOGICAL Placebo (0.9% saline)
Study Locations (1)
Ohio
- Medpace Clinical Pharmacology Unit - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-08-21 |
| Phase | Phase 1 |
What NCT07205926 shows while recruiting
NCT07205926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which IVT Shigella-04 is the first listed.
NCT07205926 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07205926 about?
NCT07205926 is a clinical study titled "First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults". Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
What is the current status of trial NCT07205926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-09. Estimated completion is 2026-08-21.
What conditions does trial NCT07205926 study?
This clinical trial studies the following conditions: Diarrhea, Shigella.
What interventions are being tested in trial NCT07205926?
The interventions under investigation include: IVT Shigella-04 (BIOLOGICAL), Placebo (0.9% saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07205926?
This trial is sponsored by Inventprise, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07205926 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07205926's enrollment target sits among peer trials
60 9th of 24 higher than 14 of 24 other Diarrhea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diarrhea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
RECRUITING · Phase 1
-
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
COMPLETED · Phase 1
-
Invaplex 50 Vaccine Dose-Ranging
COMPLETED · Phase 1
-
GI Alpha-Gal Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI